Anti-activin a antibodies and uses thereof
The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen binding fragment thereof, comprising:
a. a light chain variable domain (VL) comprising:
i. a CDR1 sequence of the amino acid sequence set forth in SEQ ID NO:11;
ii. a CDR2 sequence of the amino acid sequence set forth in SEQ ID NO:12; and
iii. a CDR3 sequence of the amino acid sequence set forth in SEQ ID NO:13; and
b. a heavy chain variable domain (VH) comprising:
i. a CDR1 sequence of the amino acid sequence set forth in SEQ ID NO:62;
ii. a CDR2 sequence of the amino acid sequence set forth in SEQ ID NO:63; and
iii. a CDR3 sequence of the amino acid sequence set forth in SEQ ID NO:64, wherein the antibody or antigen binding fragment thereof binds specifically to human activin A.
2. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof comprises:
a. a light chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:9;
b. a heavy chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:10; or
c. the light chain variable domain of (a) and the heavy chain variable domain of (b).
3. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof, that when bound to activin A:
a inhibits activin A;
b. cross-competes with a reference antibody for binding to activin A;
c. binds to the same epitope of activin A as said reference antibody;
d. binds to activin A with substantially the same Kd as said reference antibody; and/or
e. binds to activin A with substantially the smile off rate as said reference antibody; wherein said reference antibody comprises a combination of light chain and heavy chain variable domain sequences of the amino acid sequence set forth in SEQ ID NOS: 9 and 10.
4. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof, that when bound to a human activin A, inhibits binding of activin A to human activin A receptor.
5. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof possesses an in vivo biological activity of attenuating cachexia in colon tumor-bearing mice.
6. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an isolated fully human antibody that specifically binds to the cysteine knot region (amino acids C11-S33 and/or amino acids C81-E111) of activin A (SEQ ID NO:225).
7. The pharmaceutical composition of claim 6 , wherein the isolated antibody or antigen binding fragment thereof possesses an in vivo biological activity of attenuating cachexia in colon tumor-bearing mice.
8. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an isolated fully human antibody that:
a) specifically binds to the cysteine knot region, amino acids C11-S33 and/or amino acids C81-E111, of activin A (SEQ ID NO:225), wherein said fully human antibody inhibits the binding of activin A to activin A receptor in vitro, or
b) specifically binds to the cysteine knot region, amino acids C11-S33 and/or amino acids C81-E111, of activin A (SEQ ID NO:225), wherein said fully human antibody inhibits the binding of activin A to activin A receptor in vivo.
9. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof further comprises a light chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 84 and a heavy chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 214.
10. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof has a binding affinity (K D ) for human activin A of less than or equal to 1×10 −11 M.
11. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof further comprises a light chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 84, 100, or 108, and/or a heavy chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 214, 215, or 221.
12. The pharmaceutical composition according to claim 1 , further comprising one or more substances selected from the group consisting of a buffer, an antioxidant, a low molecular weight polypeptide, a protein, an amino acid, a carbohydrate, a chelating agent, and a stabilizer.
13. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is a fully human antibody.
14. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an IgG2 antibody.
15. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an IgG2 kappa antibody.
16. the pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof comprises a light chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:10.
17. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof comprises a light chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:9, a heavy chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:10, a light chain constant sequence of the amino acid sequence set forth in SEQ ID NO:84, and a heavy chain constant sequence of the amino acid sequence set forth in SEQ ID NO:214.
18. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is a fully human IgG2 antibody that comprises a light chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:9, a heavy chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:10, a light chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 84, and a heavy chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 214.
19. The pharmaceutical composition of claim 1 , wherein the isolated antibody or antigen binding fragment thereof is a fully human IgG2 antibody that consists of a light chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:9, a heavy chain variable domain sequence of the amino acid sequence set forth in SEQ ID NO:10, a light chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 84, and a heavy chain constant sequence of the amino acid sequence set forth in SEQ ID NO: 214.
20. An isolated polynucleotide comprising at least one sequence that encodes the antibody or antigen binding fragment thereof of claim 1 .
21. The polynucleotide of claim 20 , wherein the polynucleotide is a cDNA.
22. A vector comprising the polynucleotide according to claim 20 .
23. The vector according to claim 22 , which is selected from the group consisting of a plasmid, a viral vector, a non-episomal mammalian vector, an expression vector, and a recombinant expression vector.
24. An isolated cell comprising a polynucleotide according to claim 20 .
25. The isolated cell according to claim 24 , which is a hybridoma or a Chinese Hamster Ovary (CHO) cell.
26. An isolated cell into which a recombinant expression vector according to claim 22 has been introduced.
27. The isolated cell according to claim 26 , which is a hybridoma or a Chinese Hamster Ovary (CHO) cell.
28. A method of inhibiting binding of human activin A to human activin A receptor, comprising contacting human activin A with the composition of claim 1 .
29. A method of inhibiting human activin A in a subject in need thereof, comprising administering the composition of claim 1 to the subject.
30. A method for producing an antibody or antigen binding fragment thereof, comprising obtaining the cell of claim 24 and producing the antibody or antigen binding fragment thereof.
31. A method for producing an antibody or antigen binding fragment thereof, comprising obtaining the cell of claim 26 and producing the antibody or antigen binding fragment thereof.